291 related articles for article (PubMed ID: 30568147)
1. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Nakano A; Ohkubo H; Fukumitsu K; Fukuda S; Kanemitsu Y; Takemura M; Maeno K; Ito Y; Oguri T; Niimi A
Intern Med; 2019 Apr; 58(8):1141-1144. PubMed ID: 30568147
[TBL] [Abstract][Full Text] [Related]
2. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
3. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Respir Investig; 2019 Jul; 57(4):300-311. PubMed ID: 30853366
[TBL] [Abstract][Full Text] [Related]
5. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis.
Shimomura I; Abe M; Li Y; Tsushima K; Sakao S; Tanabe N; Ikusaka M; Tatsumi K
Intern Med; 2019 Apr; 58(7):965-968. PubMed ID: 30568123
[TBL] [Abstract][Full Text] [Related]
7. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
8. Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Tohoku J Exp Med; 2018 Jun; 245(2):107-114. PubMed ID: 29925700
[TBL] [Abstract][Full Text] [Related]
9. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
10. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella F; Kreuter M; Hagmeyer L; Neurohr C; Keller C; Kohlhaeufl MJ; Müller-Quernheim J; Milger K; Prasse A;
Respiration; 2016; 92(2):98-106. PubMed ID: 27544537
[TBL] [Abstract][Full Text] [Related]
11. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Yoon HY; Park S; Kim DS; Song JW
Respir Res; 2018 Oct; 19(1):203. PubMed ID: 30340638
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
14. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
[TBL] [Abstract][Full Text] [Related]
15. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
16. Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
Miyamoto A; Morokawa N; Takahashi Y; Ogawa K; Takeyasu M; Murase K; Hanada S; Uruga H; Mochizuki S; Takaya H; Kurosaki A; Kishi K
Intern Med; 2016; 55(6):657-61. PubMed ID: 26984086
[TBL] [Abstract][Full Text] [Related]
17. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
[TBL] [Abstract][Full Text] [Related]
20. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
